How Does a Pain Relief Patch Get From Raw Menthol Crystal to Sealed Foil Pouch in 9 Days? (2026 Process Walkthrough from KONGDY)

How Does a Pain Relief Patch Get From Raw Menthol Crystal to Sealed Foil Pouch in 9 Days? (2026 Process Walkthrough from KONGDY)

When buyers ask "how does a pain relief patch get from raw menthol crystal to sealed foil pouch in 9 days," the answer is a tightly choreographed 5-stage process with 3 mandatory quality gates that KONGDY has refined since 1989. After walking 38 brand owners through our 100,000-class GMP workshop from 2024 to 2026, production lead Liu Jianhua (28 years in transdermal patches) and regulatory lead Wang Lei (16 years in pharmaceutical patches) have documented the exact 9-day timeline, 5-stage quality gate, and 5-step production cost structure. This guide walks through the 9 days, the 5 production stages, the 5-step production cost calculator, and the EU MDR Class I + FDA OTC Monograph + Japan PMD + China NMPA + Korea MFDS regulatory map you need to verify your OEM contract before you ship your next 50,000-unit order.

Question 1: What Does the Raw Material Receiving Stage Look Like (Day 1)?

Day 1 of the pain relief patch production timeline begins with raw material receiving and inbound quality control. We receive four categories of materials at our Henan facility: (1) active pharmaceutical ingredients (API) including menthol crystal (CAS 2216-51-5), L-menthol (CAS 89-78-1), camphor (CAS 76-22-2), and lidocaine base (CAS 137-58-6), (2) non-woven fabric (typically 30 to 80 g/m2 spunlace non-woven, sourced from Shandong and Jiangsu), (3) release liner (typically 60 to 90 g/m2 silicone-coated PET film), and (4) foil pouch material (typically 12 to 18 micron PET / 30 to 50 micron aluminum / 60 to 80 micron PE laminate). Zhang Ting (regulatory affairs lead, 11 years) reviews each incoming material certificate of analysis (CoA) for compliance with the buyer-specified pharmacopeia: USP 43 for US-bound patches, EP 11 for EU-bound patches, JP 18 for Japan-bound patches, and ChP 2025 for China-bound patches.

The day 1 quality gate verifies 7 parameters: menthol content above 99.5% by gas chromatography, lidocaine content above 99.0% by HPLC, camphor content above 96.0% by GC, non-woven fabric GSM within plus or minus 5% of specification, release liner peel strength between 8 and 25 g/25mm, foil pouch heat-seal strength above 1.5 kg/15mm, and microbial limits below 100 CFU/g for non-sterile products. Any failure on these 7 parameters triggers a material rejection and re-order from the upstream supplier. In 2025, our inbound rejection rate was 2.3% across 1,847 raw material lots, with the most common failure being menthol content below 99.5% due to supply chain variability from Indonesian and Indian menthol sources.

Question 2: How Do You Compound the Hydrogel Matrix (Day 2 to Day 3)?

Day 2 to Day 3 covers the hydrogel matrix compounding, which is the most sensitive production stage in pain relief patch manufacturing. Liu Jianhua's team operates four compounding reactors (500L, 1000L, 2000L, and 5000L) at our Henan facility, each with temperature control to plus or minus 0.5 degrees C and vacuum degassing capability down to -0.08 MPa. The compounding formula for a 200 kg batch typically includes menthol 6 to 12 kg (3% to 6% w/w), lidocaine 4 to 8 kg (2% to 4% w/w), camphor 2 to 4 kg (1% to 2% w/w), glycerin 30 to 50 kg (15% to 25% w/w), sodium polyacrylate 8 to 16 kg (4% to 8% w/w), tartaric acid 2 to 4 kg (1% to 2% w/w), PVP K-90 4 to 8 kg (2% to 4% w/w), methylparaben 0.4 to 0.8 kg (0.2% to 0.4% w/w), and purified water q.s. to 200 kg. The compounding process follows a 6-step procedure: water charging (40 to 45 degrees C), glycerin and sodium polyacrylate addition under high-shear mixing at 800 rpm for 20 minutes, active ingredient addition under low-shear mixing at 200 rpm for 30 minutes, pH adjustment to 5.5 to 6.5 with tartaric acid, vacuum degassing at -0.08 MPa for 30 minutes, and final viscosity check at 25,000 to 45,000 cps Brookfield at 25 degrees C.

The day 2 to day 3 quality gate verifies 5 parameters: active ingredient content by HPLC within plus or minus 5% of label claim, pH within 5.5 to 6.5, viscosity within 25,000 to 45,000 cps, appearance as a clear homogeneous gel without visible particles, and microbial limits below 100 CFU/g before filling. Any failure on these 5 parameters triggers a batch rework or rejection. In 2025, our compounding rework rate was 1.1% across 4,267 batches, with the most common failure being pH below 5.5 due to tartaric acid under-charging, which our quality team corrected by adding a 0.1% sodium citrate buffer step in 2025 Q3.

Question 3: How Do You Coat, Laminate, and Die-Cut the Patch (Day 4 to Day 5)?

Day 4 to Day 5 covers the coating, lamination, and die-cutting stage, which is where the hydrogel matrix is transformed into individual patch units. Our coating line uses a comma-bar coater with a coating width of 1,000 mm and a coating weight tolerance of plus or minus 5 g/m2. The typical coating weight for a pain relief patch is 280 to 380 g/m2 (wet weight before drying). After coating, the hydrogel matrix passes through a 3-zone drying oven at 60 to 80 degrees C with a residence time of 4 to 8 minutes, achieving a final moisture content below 8% w/w. The dried hydrogel film is then laminated with non-woven fabric and release liner through a 3-roller laminator at 40 to 60 degrees C with a lamination pressure of 0.3 to 0.5 MPa.

The die-cutting stage uses a rotary die-cutter with a tolerance of plus or minus 0.3 mm on patch dimensions. Standard patch sizes range from 50 mm x 70 mm (small, 3.5 g/patch) to 100 mm x 130 mm (large, 13.0 g/patch), with the most common size being 70 mm x 100 mm (7.0 g/patch). The day 4 to day 5 quality gate verifies 6 parameters: coating weight within plus or minus 5 g/m2 of specification, moisture content below 8% w/w, lamination peel strength above 0.8 kg/25mm, die-cut dimensional tolerance within plus or minus 0.3 mm, edge cleanliness without hydrogel squeeze-out, and 100% visual inspection for foreign particles. In 2025, our die-cut defect rate was 0.42% across 86 million patches produced, with the most common defect being hydrogel squeeze-out at the patch edge due to over-thickness hydrogel matrix above 0.4 mm.

Question 4: How Do You Pack, Seal, and Carton the Finished Patches (Day 6 to Day 8)?

Day 6 to Day 8 covers the pouch packing, sealing, and carton packaging stage. Each individual patch is placed inside a foil pouch (typically 70 mm x 130 mm for the 70 mm x 100 mm patch size) and heat-sealed with a temperature of 160 to 180 degrees C, a sealing pressure of 0.4 MPa, and a dwell time of 1.2 to 1.8 seconds. After heat-sealing, the foil pouches are inspected for seal integrity (bubble test under 30 kPa for 5 seconds) and visual defects. The accepted pouches are then placed into inner boxes (typically 5 to 10 patches per box), and the inner boxes are placed into master cartons (typically 100 to 500 patches per master carton) with a 6-side corrugated cardboard construction meeting ISTA 3A drop test standards.

The day 6 to day 8 quality gate verifies 5 parameters: heat-seal strength above 1.5 kg/15mm across the full seal width, seal integrity under 30 kPa bubble test for 5 seconds, correct batch number and expiry date printing on each foil pouch (laser inkjet), correct inner box and master carton labeling per the buyer's artwork specification, and master carton weight within plus or minus 0.5 kg of specification. In 2025, our packing rejection rate was 0.18% across 86 million patches, with the most common failure being heat-seal leak due to foil pouch laminate contamination from machine oil, which our engineering team corrected by adding an automatic foil cleaning station in 2025 Q4.

Question 5: What Are the 9-Day Production Timeline, Cost, and Regulatory Map?

The 9-day production timeline from raw material receiving to finished carton-ready product is divided into 5 stages with 3 mandatory quality gates. Stage 1 (Day 1) is raw material receiving with a 2.3% rejection rate. Stage 2 (Day 2 to Day 3) is hydrogel matrix compounding with a 1.1% rework rate. Stage 3 (Day 4 to Day 5) is coating, lamination, and die-cutting with a 0.42% defect rate. Stage 4 (Day 6 to Day 8) is packing, sealing, and carton packaging with a 0.18% rejection rate. Stage 5 (Day 9) is finished product release testing and certificate of analysis (CoA) issuance.

The 5-step production cost calculator for a 70 mm x 100 mm pain relief patch with menthol 5% + lidocaine 4% + camphor 2% is as follows. Step 1 raw material cost is USD 0.045 per patch (active ingredients 0.020, non-woven fabric 0.008, release liner 0.005, foil pouch 0.012). Step 2 labor cost is USD 0.018 per patch (compounding 0.006, coating 0.005, die-cutting 0.003, packing 0.004). Step 3 overhead cost is USD 0.012 per patch (GMP workshop depreciation 0.005, utilities 0.004, QC lab 0.003). Step 4 packaging cost is USD 0.022 per patch (inner box 0.008, master carton 0.006, label and leaflet 0.008). Step 5 total ex-works cost is USD 0.097 per patch. The MOQ-based pricing tiers are: 10,000 patches at USD 0.145 per patch, 50,000 patches at USD 0.121 per patch, 100,000 patches at USD 0.108 per patch, 300,000 patches at USD 0.097 per patch, and 1,000,000 patches at USD 0.088 per patch.

The 5-jurisdiction regulatory map for pain relief patches is: EU MDR Class I (Rule 1, non-invasive, transient use) under MDR 2017/745 Annex VIII requires a Declaration of Conformity, technical documentation per Annex II and III, and EUDAMED registration. FDA OTC Monograph (lidocaine 4% topical analgesic, menthol 5% topical analgesic, camphor 3% topical analgesic) under 21 CFR Part 701 requires an NDC number, FDA registration and listing, and cosmetic or drug labeling compliance. Japan PMD under 薬機法 requires PMDA notification for lidocaine-containing patches under 医薬部外品 classification. China NMPA under 药监械（准）字 requires a class II medical device registration certificate for patches making medical claims. Korea MFDS under 医療機器法 requires MFDS notification for pain relief patches with lidocaine.

Question 6: What Are the 8 Red Flags vs Good Signs in a Pain Relief Patch OEM Audit?

The eight red flags below are the most common quality control failures we see in pain relief patch OEM audits. If your supplier shows any of these signs during the audit, you should either request a third-party audit or move to a different supplier before signing the next 50,000-unit contract.

Red flag 1: raw material receiving without pharmacopeia-specific CoA review - good sign is a pharmacopeia-specific CoA review log (USP / EP / JP / ChP) signed by the QC manager. Red flag 2: hydrogel compounding without vacuum degassing - good sign is a vacuum degassing record at -0.08 MPa for 30 minutes per batch. Red flag 3: coating weight tolerance above plus or minus 10 g/m2 - good sign is a coating weight certificate at plus or minus 5 g/m2.

Red flag 4: die-cut dimensional tolerance above plus or minus 0.5 mm - good sign is a die-cut dimensional certificate at plus or minus 0.3 mm. Red flag 5: heat-seal strength below 1.5 kg/15mm - good sign is a heat-seal strength test report at 1.5 to 2.5 kg/15mm. Red flag 6: no batch number traceability - good sign is a batch number and expiry date printed on each individual foil pouch with laser inkjet.

Red flag 7: no microbial limits test on finished product - good sign is a microbial limits test certificate below 100 CFU/g for non-sterile products per USP 61/62 or EP 2.6.12/2.6.13. Red flag 8: no pharmacopeia-specific stability study - good sign is a 6-month accelerated stability study at 40 degrees C / 75% RH per ICH Q1A with assay, content uniformity, and microbial limits test results.

Question 7: What Does the 2026 Pain Relief Patch Market Data Say About the Future of Hydrogel Manufacturing?

The global pain relief patch market reached USD 5.2 billion in 2025 according to Statista's 2025 Topical Pain Relief report, with hydrogel-based patches growing at 13% CAGR through 2030. Mintel's 2025 Pain Management report noted that 41% of US adults have used a topical pain relief product in the past 6 months, with lidocaine-containing patches showing the highest satisfaction rate at 78%. The 2026 trend is moving toward dual-active patches (lidocaine + menthol + capsaicin triple combination) and AI-assisted formulation tools that allow brands to optimize the active ingredient ratio for specific pain conditions (neuropathic pain, musculoskeletal pain, post-surgical pain).

Looking at the EU MDR Class I (Rule 1) for pain relief patches, the FDA OTC Monograph system under 21 CFR Part 701, and the China NMPA class II medical device registration framework, the regulatory environment for pain relief patches is becoming stricter in three areas: lidocaine content uniformity (the FDA requires a content uniformity test below RSD 6% per USP 905), heat-seal strength documentation (the EU requires a heat-seal strength test report at 1.5 to 2.5 kg/15mm per EN 868-5), and pharmacopeia-specific stability study (the FDA requires a 6-month accelerated stability study at 40 degrees C / 75% RH per ICH Q1A). For brands planning 2026 launches, the most important supply chain investment is a third-party audit of the OEM's compounding vacuum degassing record and the heat-seal strength test report, because under-vacuum compounding accounts for 73% of the content uniformity failures we have documented since 2024.

If you are evaluating a pain relief patch OEM for a 2026 launch, request the following five documents before signing the contract: (1) pharmacopeia-specific CoA review log (USP / EP / JP / ChP), (2) vacuum degassing record at -0.08 MPa for 30 minutes per batch, (3) coating weight certificate at plus or minus 5 g/m2, (4) heat-seal strength test report at 1.5 to 2.5 kg/15mm, (5) 6-month accelerated stability study at 40 degrees C / 75% RH per ICH Q1A. For EU launches, also request the EU MDR Class I Declaration of Conformity and the EUDAMED registration confirmation. For a deeper dive into pain relief patch formulation, see our related guide on pain relief patch troubleshooting. For a deeper dive into regulatory pathways, see our related guide on EU MDR Class I for pain relief patches.

About KONGDY

KONGDY (Henan Kongdy Medical Devices Co., LTD.) was founded in 1989 and is headquartered in Henan Province, China. The company operates a 100,000-class GMP workshop (built 2008) and holds the ISO 13485 medical device QMS European Standard Certification (since 2014). Product lines include pain relief patches, slimming patches, capsicum plasters, heat patches, cooling gel patches, detox foot patches, steam eye masks, mosquito repellent patches, and nose strips. For pain relief patch OEM inquiries, contact our production lead Liu Jianhua or regulatory lead Wang Lei.